Page 75 - 南京医科大学自然版

第44卷第12期 刘加宝，张艳娟，王连生，等. 维立西呱联合“新四联”药物对扩张型心肌病心衰患者的治疗效果分析［J］.
2024年12月 南京医科大学学报（自然科学版），2024，44（12）：1682-1689 ·1689 ·

［15］MERLO M，CANNATÀ A，GOBBO M，et al. Evolving con⁃ Heart J，2017，38（15）：1119-1127
cepts in dilated cardiomyopathy［J］. Eur J Heart Fail， ［19］ARMSTRONG P W，LAM C S P，ANSTROM K J，et al. Ef⁃

2018，20（2）：228-239 fect of vericiguat vs placebo on quality of life in patients
［16］ARMSTRONG P W，ROESSIG L，PATEL M J，et al. A with heart failure and preserved ejection fraction：the VI⁃
multicenter，randomized，double ⁃ blind，placebo ⁃ con⁃ TALITY ⁃ HFpEF randomized clinical trial［J］. JAMA，
trolled trial of the efficacy and safety of the oral soluble 2020，324（15）：1512-1521
guanylate cyclase stimulator：the VICTORIA trial［J］. ［20］LAM C S P，GICZEWSKA A，SLIWA K，et al. Clinical
JACC Heart Fail，2018，6（2）：96-104 outcomes and response to vericiguat according to index
［17］COATS A J S，TOLPPANEN H. Drug treatment of heart heart failure event：insights from the VICTORIA trial［J］.
failure with reduced ejection fraction：defining the role of JAMA Cardiol，2021，6（6）：706-712
vericiguat［J］. Drugs，2021，81（14）：1599-1604 ［21］PATEL J，RASSEKH N，FONAROW G C，et al. Guideline⁃
［18］PIESKE B，MAGGIONI A P，LAM C S P，et al. Vericiguat directed medical therapy for the treatment of heart failure
in patients with worsening chronic heart failure and pre⁃ with reduced ejection fraction［J］. Drugs，2023，83（9）：
served ejection fraction：results of the soluble guanylate 747-759
cyclase stimulator in heart failure patients with PRE⁃ ［收稿日期］ 2024-07-11
SERVED EF（SOCRATES⁃PRESERVED）study［J］. Eur （本文编辑：戴王娟）

（上接第1661页） ［16］ ZHAO J L，RAO D S，BOLDIN M P，et al. NF⁃kappaB

nosis and therapy［J］. Int J Mol Sci，2022，23（13）：7167 dysregulation in microRNA ⁃ 146a ⁃ deficient mice drives
［10］YU H R，HUANG L H，LI S C. Roles of microRNA in the the development of myeloid malignancies［J］. Proc Natl
immature immune system of neonates［J］. Cancer Lett， Acad Sci USA，2011，108（22）：9184-9189
2018，433：99-106 ［17］HE X B，JING Z Z，CHENG G F. MicroRNAs：new regula⁃
［11］GABISONIA K，PROSDOCIMO G，AQUARO G D，et al. tors of Toll⁃like receptor signalling pathways［J］. Biomed
MicroRNA therapy stimulates uncontrolled cardiac repair Res Int，2014，2014：945169
after myocardial infarction in pigs［J］. Nature，2019，569 ［18］SUN J，LIAO Z，LI Z Y，et al. Down⁃regulation miR⁃146a⁃
（7756）：418-422 5p in Schwann cell ⁃ derived exosomes induced macro⁃
［12］NAHID M A，SATOH M，CHAN E K. MicroRNA in TLR phage M1 polarization by impairing the inhibition on
signaling and endotoxin tolerance［J］. Cell Mol Immunol， TRAF6/NF⁃κB pathway after peripheral nerve injury［J］.
2011，8（5）：388-403 Exp Neurol，2023，362：114295
［13］PENG X F，HE F，MAO Y L，et al. miR⁃146a promotes ［19］VAN GOLEN R F，VAN GULIK T M，HEGER M. The
M2 macrophage polarization and accelerates diabetic sterile immune response during hepatic ischemia/reperfu⁃
wound healing by inhibiting the TLR4/NF⁃κB axis［J］. J sion［J］. Cytokine Growth Factor Rev，2012，23（3）：69-84
Mol Endocrinol，2022，69（2）：315-327 ［20］XU J Q，GAO C G，HE Y J，et al. NLRC3 expression in
［14］ZHANG Y Q，LE X，ZHENG S，et al. MicroRNA⁃146a⁃5p⁃ macrophage impairs glycolysis and host immune defense
modified human umbilical cord mesenchymal stem cells by modulating the NF⁃κB⁃NFAT5 complex during septic
enhance protection against diabetic nephropathy in rats immunosuppression［J］. Mol Ther，2023，31（1）：154-173
through facilitating M2 macrophage polarization［J］.Stem ［21］ ZENG Q，YE L，LING M Y，et al. TLR4/TRAF6/NOX2
Cell Res Ther，2022，13（1）：171 signaling pathway is involved in ventilation⁃induced lung
［15］ BOLDIN M P，TAGANOV K D，RAO D S，et al. miR ⁃ injuryviaendoplasmicreticulumstressinmurinemodel［J］.
146a is a significant brake on autoimmunity，myeloproli⁃ Int Immunopharmacol，2021，96：107774
feration，and cancer in mice［J］. J Exp Med，2011，208 ［收稿日期］ 2024-08-08
（6）：1189-1201 （本文编辑：蒋 莉）